keyword
Keywords Adenocarcinoma from an unknown...

Adenocarcinoma from an unknown primary

https://read.qxmd.com/read/37406274/detecting-undetectable-epidemiology-etiology-and-diagnosis-of-carcinoma-of-unknown-primary-systematic-review
#21
Justyna Ostojewska, Iga Wieczorek, Olaf Pachciński, Wojciech Zdziennicki, Franciszek Burdan
Carcinoma of unknown primary (CUP) is a heterogeneous group of oncological diseases in which it is impossible to determine the primary tumor. The incidence is 3-5% of oncologic patients, but the survival time varies from 6 weeks to 5 months. The diagnostics should begin with a clinical evaluation and basic laboratory tests. For CUP placed in head and neck the positron emission tomography - computed tomography is recommended; pancreatic or lung neoplasms are diagnosed with the computed tomography as well. Recently, the magnetic resonance, especially whole-body diffusion-weighted imaging has been introduced to the imaging panel...
April 30, 2023: Folia Medica Cracoviensia
https://read.qxmd.com/read/37390616/phase-i-ii-trial-of-carboplatin-nab-paclitaxel-and-pembrolizumab-for-advanced-non-small-cell-lung-cancer-hoosier-cancer-research-network-lun13-175
#22
JOURNAL ARTICLE
Ryan D Gentzler, Nisha A Mohindra, Shadia I Jalal, Karen L Reckamp, Richard D Hall, Nasser H Hanna, Young Kwang Chae, Marianna Koczywas, Irene B Helenowski, Jyoti D Patel
BACKGROUND: Combination chemotherapy and immunotherapy regimens have significantly improved survival for patients with previously untreated advanced non-small cell lung cancer (NSCLC). Improvements in overall survival (OS) in two separate pembrolizumab trials have demonstrated survival improvements over chemotherapy alone, regardless of PD-L1 status. The optimal chemotherapy backbone for combination with immunotherapy is unknown. We hypothesized nab-paclitaxel may be a well-suited platinum partner to use in combination with checkpoint inhibitor therapy for both adenocarcinoma and squamous histology and conducted a phase I/II trial to assess the efficacy of this regimen in advanced NSCLC...
January 5, 2024: Oncologist
https://read.qxmd.com/read/37355521/egfr-mutation-is-a-prognostic-factor-in-lung-cancer-patients-with-pleural-dissemination-detected-during-or-after-surgery
#23
JOURNAL ARTICLE
Toshiya Fujiwara, Kazuhiko Shien, Motoki Matsuura, Junichi Soh, Hiromasa Yamamoto, Soshi Takao, Yuho Maki, Tsuyoshi Ueno, Ryujiro Sugimoto, Ken Suzawa, Mikio Okazaki, Hiroyuki Tao, Makio Hayama, Masafumi Kataoka, Yoshifumi Sano, Hidetoshi Inokawa, Motohiro Yamashita, Osamu Kawamata, Kazuhiko Kataoka, Shinichi Toyooka
BACKGROUND: Primary lung tumors are sometimes resected when either pleural dissemination (PD) or malignant pleural effusion (MPE) exists. This study clarified the prognostic factors for non-small cell lung cancer (NSCLC) with either PD and MPE, or both, detected during or after surgery. PATIENTS AND METHODS: We examined patients with NSCLC from a multicenter database who had either PD, MPE, or both, detected during or after surgery between 2005 and 2015. Hazard ratios and 95% confidence intervals were estimated using the Cox proportional hazards model adjusted for potential confounding factors...
June 25, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/37348348/randomized-phase-ii-adjuvant-trial-to-compare-two-treatment-durations-of-icotinib-2-years-versus-1-year-for-stage-ii-iiia-egfr-positive-lung-adenocarcinoma-patients-icompare-study
#24
RANDOMIZED CONTROLLED TRIAL
C Lv, R Wang, S Li, S Yan, Y Wang, J Chen, L Wang, Y Liu, Z Guo, J Wang, Y Pei, L Yu, N Wu, F Lu, F Gao, J Chen, Y Liu, X Wang, S Li, B Han, L Zhang, Y Ma, L Ding, Y Wang, X Yuan, Y Yang
BACKGROUND: Despite the prolonged median disease-free survival (DFS) by adjuvant targeted therapy in non-small-cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, the relationship between the treatment duration and the survival benefits in patients remains unknown. PATIENTS AND METHODS: In this multicenter, randomized, open-label, phase II trial, eligible patients aged 18-75 years with EGFR-mutant, stage II-IIIA lung adenocarcinoma and who had not received adjuvant chemotherapy after complete tumor resection were enrolled from eight centers in China...
August 2023: ESMO Open
https://read.qxmd.com/read/37270871/s-1-maintenance-therapy-in-caucasian-patients-with-metastatic-esophagogastric-adenocarcinoma-final-results-of-the-randomized-aio-mateo-phase-ii-trial
#25
JOURNAL ARTICLE
G Stocker, S Lorenzen, T Ettrich, A-L Herz, F Longo, A Kiani, M Venerito, J Trojan, R Mahlberg, N Moosmann, B Chibaudel, S Kubicka, R Greil, S Daum, M Geissler, J Larcher-Senn, G Keller, F Lordick, G M Haag
PURPOSE: Platinum-fluoropyrimidine combinations are standard of care for treatment of metastatic esophagogastric adenocarcinoma. The optimal duration of first-line chemotherapy is unknown, however, and maintenance strategies have not yet been established. DESIGN: MATEO is an international randomized phase II trial exploring efficacy and safety of S-1 maintenance therapy in human epidermal growth factor receptor 2 (HER2)-negative advanced esophagogastric adenocarcinoma...
June 2, 2023: ESMO Open
https://read.qxmd.com/read/37265412/fda-approval-summary-selpercatinib-for-the-treatment-of-advanced-ret-fusion-positive-solid-tumors
#26
JOURNAL ARTICLE
Elizabeth S Duke, Diana Bradford, Michelle Marcovitz, Anup K Amatya, Pallavi S Mishra-Kalyani, Emily Nguyen, Lauren S L Price, Jeanne Fourie Zirkelbach, Yangbing Li, Youwei Bi, Jeffrey Kraft, Sarah E Dorff, Barbara Scepura, Maritsa Stephenson, Idara Ojofeitimi, Abhilasha Nair, Yu Han, Zivana Tezak, Steven J Lemery, Richard Pazdur, Erin Larkins, Harpreet Singh
On September 21, 2022, the FDA granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for the treatment of adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. The approval was based on data from Study LOXO-RET-17001 (LIBRETTO-001; NCT03157128), an international, non-randomized, multi-cohort clinical trial that included patients with advanced solid tumors harboring RET alterations...
September 15, 2023: Clinical Cancer Research
https://read.qxmd.com/read/37219515/fda-approval-summary-selpercatinib-for-the-treatment-of-advanced-ret-fusion-positive-solid-tumors
#27
JOURNAL ARTICLE
Elizabeth S Duke, Diana Bradford, Michelle Marcovitz, Anup K Amatya, Pallavi S Mishra-Kalyani, Emily Nguyen, Lauren S L Price, Jeanne Fourie Zirkelbach, Yangbing Li, Youwei Bi, Jeffrey Kraft, Sarah E Dorff, Barbara Scepura, Maritsa Stephenson, Idara Ojofeitimi, Abhilasha Nair, Yu Han, Zivana Tezak, Steven J Lemery, Richard Pazdur, Erin Larkins, Harpreet Singh
On September 21, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo®, Eli Lilly and Company) for the treatment of adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. The approval was based on data from Study LOXO-RET-17001 (LIBRETTO-001; NCT03157128), an international, non-randomized, multi-cohort clinical trial which included patients with advanced solid tumors harboring RET alterations...
May 23, 2023: Clinical Cancer Research
https://read.qxmd.com/read/37205198/molecular-characteristics-of-multiple-primary-pulmonary-nodules-under-a-three-dimensional-reconstruction-model-and-relevant-multi-omics-analyses-a-case-report
#28
Zhilin Luo, Yajie Xiao, Chengwen Luo, Liping Zhang, Runquan Zhou, Zhikun Zhao, Chao Sun, Dongfang Wu, Tianhu Wang
BACKGROUND: In addition to CT images and pathological features, many other molecular characteristics remain unknown about multiple primary lung cancer (MPLC) from intrapulmonary metastatic lung cancer. CASE PRESENTATION: In this study, we reported a patient with an early-stage MPLC with both adenocarcinoma in situ (AIS) subtype and minimally invasive adenocarcinoma (MIA) subtype. The patient was diagnosed with more than 10 nodules and underwent precise surgery assisted by three-dimensional (3D) reconstruction at the left upper lung lobe...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37069616/cribriform-adenocarcinoma-of-the-minor-salivary-glands-a-case-report
#29
JOURNAL ARTICLE
Tanya Chen, Mohammed Mamdani, Allan Vescan, Christina MacMillan, Joel Davies
BACKGROUND: Polymorphous adenocarcinoma is the third most common malignant salivary gland tumor. Within polymorphous adenocarcinoma, cribriform adenocarcinoma of salivary glands is a rare subtype and resembles papillary thyroid carcinoma histopathologically. Diagnostically, cribriform adenocarcinoma of salivary glands is challenging for pathologists and surgeons alike as initial presentation and cytologic nuclear features can be easily confused with papillary thyroid carcinoma arising from a thyroglossal duct remnant or lingual thyroid...
April 18, 2023: Journal of Medical Case Reports
https://read.qxmd.com/read/37060832/age-related-differences-in-colon-and-rectal-cancer-survival-by-stage-histology-and-tumour-site-an-analysis-of-united-states-seer-18-data
#30
JOURNAL ARTICLE
Sophie Pilleron, Diana R Withrow, Brian D Nicholson, Eva J A Morris
Age-related differences in colon and rectal cancer survival have been observed, even after accounting for differences in background mortality. To determine how stage, tumour site, and histology contribute to these differences, we extracted age-specific one-year relative survival ratio (RS) stratified by these factors. We used colon and rectal cancer cases diagnosed between 2012 and 2016 from 18 United States Surveillance Epidemiology and End Results cancer registries. For colon cancer, 1-year RS ranged from 87...
April 13, 2023: Cancer Epidemiology
https://read.qxmd.com/read/37032350/colorectal-cancer-metastases-in-thyroid-case-report-and-literature-review
#31
JOURNAL ARTICLE
Syed Mohammad Asim Hussain, Suzanne Cole, Iram Hussain
BACKGROUND: The thyroid gland is an uncommon site for metastatic deposits from non-thyroid malignancies, occurring in only 1.4 - 3% of surgical specimens where malignancy is suspected. It is even rarer for the source of thyroid metastases to be of colorectal origin. In most cases reported, colorectal metastases in the thyroid occurs many years later after the primary colorectal cancer has been diagnosed and treated. In this unique case, a primary sigmoid carcinoma metastasised to the thyroid gland and presented synchronously as a thyroid nodule...
April 10, 2023: Thyroid Research
https://read.qxmd.com/read/36988328/fatal-human-rabies-infection-with-suspected-host-mediated-failure-of-post-exposure-prophylaxis-following-a-recognized-zoonotic-exposure-minnesota-2021
#32
JOURNAL ARTICLE
Stacy M Holzbauer, Caroline A Schrodt, Rajesh M Prabhu, Rebecca J Asch-Kendrick, Malia Ireland, Carrie Klumb, Melanie J Firestone, Gongping Liu, Katie Harry, Jana M Ritter, Min Z Levine, Lillian A Orciari, Kimberly Wilkins, Pamela Yager, Crystal M Gigante, James A Ellison, Hui Zhao, Michael Niezgoda, Yu Li, Robin Levis, Dorothy Scott, Panayampalli S Satheshkumar, Brett W Petersen, Agam K Rao, W Robert Bell, Sonja M Bjerk, Sara Forrest, Wangcai Gao, Richard Dasheiff, Kari Russell, Melissa Pappas, Jessica Kiefer, Wesley Bickler, Anthony Wiseman, Joel Jurantee, R Ross Reichard, Kirk E Smith, Ruth Lynfield, Joni Scheftel, Ryan M Wallace, Jesse Bonwitt
BACKGROUND: No rabies post-exposure prophylaxis (PEP) failure has been documented in humans in the United States using modern cell-culture vaccines. In January 2021, an 84-year-old male died from rabies six months after being bitten by a rabid bat despite receiving timely rabies post-exposure prophylaxis (PEP). We investigated the cause of breakthrough infection. METHODS: We reviewed medical records, laboratory results, and autopsy findings, and performed whole genome sequencing (WGS) to compare patient and bat virus sequences...
March 29, 2023: Clinical Infectious Diseases
https://read.qxmd.com/read/36974819/treatment-of-mediastinal-endometrial-carcinoma-developed-from-extragenital-endometriosis-and-simultaneous-rectal-adenocarcinoma-in-a-55-year-old-woman
#33
JOURNAL ARTICLE
Klara Dorman, Danmei Zhang, Wolfgang G Kunz, Martin Angele, Jens Neumann, Alexander Burges, Michael VON Bergwelt-Baildon, Volker Heinemann, Stefan Boeck, Clemens Giessen-Jung
BACKGROUND/AIM: Endometriosis is a common disorder in reproductive-age women leading to a broad range of symptoms and is associated with a higher risk for endometrioid ovarian carcinoma. CASE REPORT: We report the case of a 55 year-old woman with previously undiagnosed endometriosis presenting with a large mediastinal cancer of unknown primary (CUP) and synchronous Union Internationale Contre le Cancer (UICC) stage II rectal adenocarcinoma. Histopathologically the mediastinal tumor resembled endometrial carcinoma and laparoscopically endometriotic lesions on the patient's peritoneum were detected...
April 2023: Anticancer Research
https://read.qxmd.com/read/36938247/diagnostic-accuracy-of-cell-block-and-immunohistochemistry-in-effusion-cytology
#34
JOURNAL ARTICLE
Saima Batool, Safana Sadaf, Akhtar S Chughtai, Aafia Qasim, Asma Zafar, Anum Jamil
Introduction Although the cytology of effusion fluids is considered a routine laboratory test, it has recently emerged as an essential tool in determining the primary site of origin of carcinoma of unknown primary. The sensitivity for diagnosing malignancy has enhanced with the inclusion of cytospin, cell block (CB), and immunohistochemistry (IHC) to effusion fluid cytology due to the improvement in morphological preservation and good cellular yield. The purpose of this study was to assess the diagnostic yield, sensitivity, specificity, positive predictive value, and negative predictive value of IHC and CB in effusion cytology...
February 2023: Curēus
https://read.qxmd.com/read/36895475/primary-retroperitoneal-nodal-endometrioid-carcinoma-associated-with-lynch-syndrome-a-case-report
#35
Daniela Fischerova, Umberto Scovazzi, Natacha Sousa, Tatevik Hovhannisyan, Andrea Burgetova, Pavel Dundr, Kristýna Němejcová, Rosalie Bennett, Michal Vočka, Filip Frühauf, Roman Kocian, Tereza Indrielle-Kelly, David Cibula
We report a rare case of primary nodal, poorly differentiated endometrioid carcinoma associated with Lynch syndrome. A 29-year-old female patient was referred by her general gynecologist for further imaging with suspected right-sided ovarian endometrioid cyst. Ultrasound examination by an expert gynecological sonographer at tertiary center revealed unremarkable findings in the abdomen and pelvis apart from three iliac lymph nodes showing signs of malignant infiltration in the right obturator fossa and two lesions in the 4b segment of the liver...
2023: Frontiers in Oncology
https://read.qxmd.com/read/36826817/evaluation-of-systemic-treatments-of-small-intestinal-adenocarcinomas-a-systematic-review-and-meta-analysis
#36
JOURNAL ARTICLE
Tim de Back, Isabelle Nijskens, Pascale Schafrat, Myriam Chalabi, Geert Kazemier, Louis Vermeulen, Dirkje Sommeijer
IMPORTANCE: Although small intestinal adenocarcinomas (SIAs) are rare, they have a poor prognosis, and the optimal treatment strategies are largely unknown. Because of the lack of high-quality evidence, guidelines for colorectal cancer are often followed in the treatment of SIAs. OBJECTIVE: To review the current evidence regarding survival benefit of systemic therapies, including chemotherapy, targeted agents, and immunotherapy, for patients with SIAs. DATA SOURCES: Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses, MEDLINE and Embase were searched for articles published from January 1, 2005, until June 1, 2022...
February 1, 2023: JAMA Network Open
https://read.qxmd.com/read/36822906/-secondary-tumors-localized-in-testis
#37
JOURNAL ARTICLE
Pierre Allaume, Zine-Eddine Khene, Benoît Peyronnet, Romain Mathieu, Karim Bensalah, Nathalie Rioux-Leclercq, Solène-Florence Kammerer-Jacquet
Testis tumors are uncommon in oncology, and testicular metastasis from distant solid tumors are even rarer. We present two cases encountered in our department of pathology in CHU de Rennes, France. Moreover, we collected all reported cases in the Medline/PubMed databases of non-hematopoietic secondary testis tumors in adults, excluding autopsy studies, to propose an integrative study on this topic. In total, we report 98 cases of secondary testis lesions to prostate (n=38, 38.77 %), colorectal (n=19, 19...
February 21, 2023: Annales de Pathologie
https://read.qxmd.com/read/36819515/sweet-s-syndrome-with-adenocarcinoma-of-lung-a-rare-case-report
#38
Yujie Xie, Dongmei Lai, Junli Ke, Zhengang Zhao, Wanli Lin
BACKGROUND: Sweet's syndrome is a rare inflammatory disease of unknown etiology, and its relationship with tumors is unknown at present. Sweet's syndrome in patients with solid tumors, especially adenocarcinoma of the lung, is extremely rare. At present, only 1 case of an operative patient has been reported in the literature. Diagnosing lung cancer with Sweet's syndrome is not easy, when there is a fever with an unknown cause and erythemas, especially when the erythemas do not disappear after antibiotic treatment, a skin biopsy is much important...
January 31, 2023: Annals of Translational Medicine
https://read.qxmd.com/read/36730833/strong-annexin-a10-expression-supports-a-pancreatic-primary-and-combined-annexin-a10-claudin-18-and-sox2-expression-supports-an-esophagogastric-origin-in-carcinomas-of-unknown-primary
#39
JOURNAL ARTICLE
Raymond A Isidro, Ibrahim Abukhiran, Craig D Dunseth, Matthew D Gosse, Robert M Humble, Daniel J Pelletier, Neha Varshney, Andrew M Bellizzi, Jason L Hornick
Primary tumor site determination for gastrointestinal (GI) tract and pancreaticobiliary (PB) tree carcinomas that present as metastasis of unknown primary can be problematic. Annexin A10 (ANXA10), claudin 18 (CLDN18), and trefoil factor 1 (TFF1) have been identified through expression profiling as markers of gastric lineage commitment; sex-determining region Y (SRY)-box transcription factor 2 (SOX2) expression has been reported in several tumor types, including gastric adenocarcinomas. We evaluated the diagnostic utility of immunohistochemistry for ANXA10, CLDN18, SOX2, and TFF1 for determining the site of origin for GI/PB adenocarcinomas...
April 1, 2023: American Journal of Surgical Pathology
https://read.qxmd.com/read/36722353/incidence-and-oncological-implication-of-adrenal-incidentalomas-in-esophageal-cancer-patients
#40
JOURNAL ARTICLE
J R van Doesburg, D M Voeten, M C Kalff, M I van Berge Henegouwen, S Jol, J E van den Bergh, A F Engelsman, S S Gisbertz, F Daams
Adrenal incidentalomas are regularly encountered during imaging for esophageal cancer patients, but their oncological significance remains unknown. This study aimed to describe the incidence and etiology of adrenal incidentalomas observed throughout the diagnostic workup. This retrospective cohort study included all esophageal cancer patients referred to or diagnosed in the Amsterdam UMC between January 2012 and December 2016. Radiology and multidisciplinary team meeting reports were reviewed for adrenal incidentalomas...
January 31, 2023: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
keyword
keyword
30548
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.